Court Extends Deadline for Claims Vs. Bristol-Myers
By Marius Meland
Law360, New York (November 14, 2003, 12:00 AM EST) -- The U.S. District Court for the District of Columbia has given cancer patients treated with Taxol (paclitaxel) another three months to file claims against Bristol-Myers Squibb for delaying generic competition by fraudulently obtaining patents, Idaho Attorney General Lawrence Wasden said in a statement.
Consumers who used Taxol between 1999 and February 2003 and their survivors now have until Jan. 31 to file a claim under a settlement agreement reached earlier this year.
The court has tentatively approved the settlement in the antitrust lawsuit filed by 29...